Lexicon Pharmaceuticals Says FDA Panel Opposes Zynquista for Type 1 Diabetes and Kidney Disease
Lexicon Pharmaceuticals Says FDA Panel Opposes Zynquista for Type 1 Diabetes and Kidney Disease
莱斯康制药表示，FDA委员会反对Zynquista用于1型糖尿病和肾脏疾病
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间